Literature DB >> 25995185

The prognostic value of regadenoson stress: Has the case been made?

Rami Doukky1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25995185     DOI： 10.1007/s12350-015-0179-3

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  15 in total

1.  Contemporary relevance of TID: Based on the company it keeps.

Authors:  Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2015-04-02       Impact factor: 5.952

2.  Prognostic implications of stress modality on mortality risk and cause of death in patients undergoing office-based SPECT myocardial perfusion imaging.

Authors:  Marie-France Poulin; Sarah Alexander; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2015-03-19       Impact factor: 5.952

3.  Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching.

Authors:  Fahad M Iqbal; Fadi G Hage; Ali Ahmed; Phillip J Dean; Saleem Raslan; Jaekyeong Heo; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2012-10

4.  A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging.

Authors:  Fadi G Hage; Phillip Dean; Fahad Iqbal; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2011-07-22       Impact factor: 5.952

5.  Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials.

Authors:  Maria Octavia Rangel; Raysa Morales Demori; Sarah T Voll; Marwan Wassouf; Rizcallah Dick; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2014-12-11       Impact factor: 5.952

6.  The prognostic value of regadenoson myocardial perfusion imaging.

Authors:  Fadi G Hage; Gopal Ghimire; Davis Lester; Joshua Mckay; Steven Bleich; Stephanie El-Hajj; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2015-02-14       Impact factor: 5.952

7.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

8.  Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.

Authors:  John J Mahmarian; Leif E Peterson; Jiaqiong Xu; Manuel D Cerqueira; Ami E Iskandrian; Timothy M Bateman; Gregory S Thomas; Faisal Nabi
Journal:  J Nucl Cardiol       Date:  2014-10-07       Impact factor: 5.952

9.  Reclassification of cardiovascular risk in patients with normal myocardial perfusion imaging using heart rate response to vasodilator stress.

Authors:  Fahad M Iqbal; Wael Al Jaroudi; Kumar Sanam; Aaron Sweeney; Jaekyeong Heo; Ami E Iskandrian; Fadi G Hage
Journal:  Am J Cardiol       Date:  2012-10-27       Impact factor: 2.778

10.  Safety of regadenoson in patients with end-stage renal disease.

Authors:  Wael Aljaroudi; Daniel Hermann; Fadi Hage; Jaekyeong Heo; Ami E Iskandrian
Journal:  Am J Cardiol       Date:  2009-11-18       Impact factor: 2.778
View more
  3 in total

1.  Review of Cardiovascular Imaging in the Journal of Nuclear Cardiology in 2015-Part 2 of 2: Myocardial perfusion imaging.

Authors:  Fadi G Hage; Wael A AlJaroudi
Journal:  J Nucl Cardiol       Date:  2016-02-18       Impact factor: 5.952

2.  The blood pressure response to vasodilator stress does not provide independent prognostic information.

Authors:  Eliana Reyes; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2016-08-29       Impact factor: 5.952

3.  The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.

Authors:  Rami Doukky; Ibtihaj Fughhi; Tania Campagnoli; Marwan Wassouf; Amjad Ali
Journal:  J Nucl Cardiol       Date:  2015-11-18       Impact factor: 5.952
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.